Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 26 Feb 2015 |
| Zealand reports Lyxumia® royalty revenue for 2014 and informs of developmental and regulatory updates by Sanofi | 5 Feb 2015 |
| Zealand and Helsinn announce the advance of elsiglutide into Phase IIB development for the prevention of chemotherapy-induced diarrhea | 5 Feb 2015 |
| Zealand announces a change to its Board of Directors | 2 Feb 2015 |
| Major shareholder announcement | 6 Jan 2015 |
| Financial Calendar for 2015 | 30 Dec 2014 |